Introduction
Recent advances in the understanding of immune responses have revealed that for successful T cell activation two signals are required. The first is delivered through specific recognition and interaction of T cell receptor (TCR) with the target MHC-antigenic peptide complex. The second signal is delivered through costimulatory molecules expressed on antigen presenting cells (APCs) binding to their counterpart receptors on T lymphocytes. Association with these molecules both stabilises the interaction of lymphocyte and APC and transduces costimulatory signals leading to cytokine secretion, proliferation and induction of effector function. Several cell surface molecules such as ICAM-1 and LFA-3 have been shown to have a costimulatory function but one of the dominant costimulatory pathways is provided by signalling through CD28. 1 Two ligands for CD28 have been described, B7-1 and B7-2. These ligands are expressed on the majority of professional APCs such as activated B cells, dendritic cells and macrophages. [2] [3] [4] Both the human and murine B7-1 and B7-2 genes have been cloned and shown to be members of the immunoglobulin gene superfamily. 2, [5] [6] [7] [8] [9] The potent costimulatory role of B7-1 has been demonstrated in a number of studies of T cell activation. Proliferation of T cells in response to PMA or anti-CD3 can Correspondence: MG Gilligan Received 28 November 1997; revised 28 January 1998; accepted 10 February 1998 be increased by the addition of B7-1 transfectants. 10, 11 TCR signalling in the absence of costimulation results in T cell inactivation or 'anergy' in that clone of T lymphocytes. 12 This represents an unresponsive state in which subsequent presentation of antigen, even in the presence of adequate costimulation, will fail to elicit a response. Induction of T cell anergy may be one of the mechanisms by which tumours evade recognition by the immune system. While a variety of tumours are potentially immunogenic displaying both normal levels of MHC molecules and intact antigen presentation capacity, most solid tumours do not express B7-1 or B7-2 and therefore, despite having the capacity to deliver the antigenic signal, render T cells anergic. The B7/CD28 costimulatory pathway has been exploited to enhance specific immune responses against tumours to generate antitumour immunity. Genetically engineered tumour cells constitutively expressing B7-1 have been shown to be rejected in a variety of murine models, and in some cases protection against further challenge with unmodified tumour has been shown. [13] [14] [15] [16] [17] [18] There is now a considerable body of literature describing studies using B7-1 expressing murine tumour cells, but the data available on the effect of B7-1 gene transfer to human tumour cells (or of other immunotherapeutic genes) is relatively limited. Most of the current attempts to develop cancer vaccines in humans have been directed towards melanoma or renal cell cancer both of which are considered to be relatively immunogenic tumour types. There are comparatively few reports on immunotherapy applied to ovarian and cervical cancers although it is known that these tumours can serve as targets for T cell responses.
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In this study we have engineered a recombinant, replication defective adenovirus vector carrying a human B7-1 gene for use in gene therapy for ovarian and cervical cancer. Replication defective adenovirus vectors are in many ways uniquely suited for use in gene therapy. These properties have been extensively reviewed 23, 24 and include the ability to prepare high titre virus capable of efficient infection of a range of proliferating and nonproliferating cell types in vitro and in vivo. We have demonstrated that the recombinant virus described in this study provides an efficient means of achieving B7-1 expression in a number of cervical and ovarian cell lines, as well as primary cultures of ovarian tumour cells. We then demonstrated that B7-1 expression can enhance the immunogenicity of these cells thus meeting a necessary requirement for future development of tumour vaccines by this route.
Results
B7-1 expression at the cell surface
In agreement with the literature, the tumour cell lines in this study were found not to express endogenous B7-1 (results not shown). Different concentrations of RAd-B7-1 were used to infect the ovarian tumour cell line IGROV-1 to determine the optimum amount of virus for use in infection experiments. A recombinant adenovirus expressing B7-1 (RAd-B7-1) was constructed ( Figure 1 OVCAR3 cells and hence a higher percentage of cells remaining positive.
Efficiency of RAd-B7-1 infection of ovarian and cervical tumour cell lines RAd-B7-1 virus was used to infect a number of established ovarian and cervical tumour cell lines at an MOI of 30 p.f.u. per cell and cells were assessed for B7-1 expression by FACS analysis 48 h after infection. A fairly wide range of B7-1 expression at the cell surface was seen between the ovarian and cervical cell lines with most giving between 40-95% positive cells ( Table 1 ). The ovarian cell line A2780 was shown to be relatively resistant to adenoviral infection as an MOI of 30 p.f.u. per cell resulted in only 4.4% of cells positive (Table 1A) . A high MOI of 500 p.f.u. per cell resulted in 79% positive cells but with a relatively low mean fluoresence intensity (data not shown). In all cases the number of positive cells and the amount of B7-1 protein produced could be increased by increasing the amount of virus used during infection (data not shown).
RAd-B7-1 infection of primary ovarian tumour cells
Having demonstrated that the established cell lines are susceptible to adenovirus infection we next examined the infectivity of primary ovarian tumour cells. Tumour cells directly cultured from the ascitic fluid of seven patients with adenocarcinoma of the ovary were studied for the expression of a number of different cellular markers in order to verify cell type. Markers studied included MHC class I and II, p53, CA125, cytokeratin, epithelial membrane antigen, vimentin, HER2/neu, CEA and 5T4. In all cases, the use of these markers confirmed cell cultures consisting of greater than 90% tumour cells (data not shown). Tumour cells infected with RAd-B7-1 at an MOI of 30 p.f.u. per cell gave high levels of B7-1 expression at the cell surface in six out of seven cases (Table 2 ). In the case of patient 4 where only 11% of cells were found to be positive, B7-1 expression could be increased to 60% of cells when an MOI of 300 p.f.u. per cell was used.
Increased immunogenicity of tumour cells expressing B7-1
To address the question of whether tumour cells modified to express B7-1 are more immunogenic, PBLs from three healthy donors were stimulated with an ovarian tumour cell line and a cervical cell line infected with RAd-B7-1 or control adenovirus RAd35. Cells were incubated with IFN␥ following infection and this was shown by flow cytometry to upregulate both MHC class I and class II expression (data not shown). a low level of T cell proliferation while cells expressing B7-1 induced a strong proliferative response that was dependent on the number of tumour cells. A slightly different pattern of proliferation was seen when cervical tumour cells HeLa were used as stimulators ( Figure  5d -f). In this case an increase in proliferation was seen with up to 1 × 10 4 stimulator cells, but thymidime uptake was lower with 2 x 10 4 stimulator cells. This decrease in proliferation was seen in both control cultures and cultures stimulated with RAd-B7-1-infected HeLa cells.
The MLTC experiment was repeated using freshly isolated ascitic ovarian tumour cells OTCMG61 (Figure 6a-c) and an early passage cell culture derived from a solid ovarian tumour OvCaMG75 (Figure 6d-f) . Ascitic ovarian tumour cells were infected at an MOI of 30 p.f.u. per cell of RAd-B7-1 or RAd35 while those from the solid tumour were infected at an MOI of 300 p.f.u. per cell (57.6% of cells positive). As seen in Figure 6 , the same pattern of response is seen using PBLs from three donors, that is an increased proliferative response to cells expressing B7-1 compared with control. That the increased T cell proliferation was due to the expression of B7-1 was confirmed by use of neutralising anti-B7-1 antibody added at the initiation of the MLTC culture ( Figure 7 ). Complete inhibition of excess proliferation relative to control cells was achieved by the addition of 2.5 g/ml of BB-1 antibody. Addition of an equal concentration of isotype control antibody did not reduce the B7-1 enhanced proliferation, and none of the antibodies had any effect on control values.
Discussion
The present investigation was undertaken to determine if an adenoviral vector would be an efficient agent to use for gene transfer of B7-1 in the modification of ovarian and cervical tumour cells for use in immunotherapy. Previously B7-1 has been expressed in several tumour cell lines following transfection or retroviral transfer of DNA followed by drug selection of positive cells. The low titre obtained from retroviral vectors, their ability to infect only dividing cells and the consequent requirement for multiple cycles of infection, or for drug selection of transduced cells, limits their application for modification of tumour cells for gene therapy, particularly for direct in vivo viral delivery approaches. These vectors may be suitable for modification of tumour cells without extended culture ex vivo as Jaffee et al 25 reported high efficiency retroviral gene transfer into a number of primary human tumour explants without drug selection. Sule-Suso et al 26 
Figure 6 Increased proliferation of allogeneic PBLs stimulated with B7-1 positive primary ovarian tumour cells. (a-c) Proliferation of PBLs from three donors after 6-day culture with irradiated ascitic ovarian tumour cells (patient 2, OTCMG61). ć Cells preinfected with RAd35; b cells preinfected with RAd-B7-1, MOI 30 p.f.u. per cell. (d-f) Proliferation of PBLs from three donors after 6-day culture with irradiated early passage ovarian tumour cells OvCaMG75 derived from a solid tumour. ᭛ Cells preinfected with RAd35; ᭜ cells preinfected with RAd-B7-1, MOI 300 p.f.u. per cell. Each point represents the mean (± s.e.m.) of six determinations. The results shown are typical of those found in three separate experiments.
transfected and selected a cloned melanoma cell line with B7-1, and showed increased stimulation of both autologous and allogeneic PBLs compared with parental unmodified melanoma cells. An increase in the cytotoxic activity of allogeneic PBLs was also described. Dohring et al 27 used a retroviral vector to deliver B7-1 to a melanoma, ovarian and myelomonocytic leukemia cell line. Cells were selected for G418 resistance then used to stimulate allogeneic PBLs. Increases in proliferation were seen with all three lines, and the expanded T cells showed efficient lysis of the wild-type unmodified tumour cells. Previous studies have also depended on the establishment of long-term cultures of tumour cells which, in the context of developing a clinically useful cancer vaccine, is time-consuming and often inefficient, possibly resulting in the loss of critical tumour antigens. 28 This study describes the construction and application of a recombinant B7-1 adenovirus. This vector can rapidly and efficiently infect ovarian and cervical tumour cell lines with B7-1 expression detectable at the cell surface within 12 h following infection. Expression is stable and detectable up to 10 days as determined by a time course of gene expression. Constitutive gene expression of B7-1 is not required for the effector phase of T cell lysis since B7-CD28 interaction is crucial in the induction phase of a cytotoxic response but not during the lytic phase when unmodified cells may be recognised and killed. 29 A range of virus dilutions was used to determine the optimal MOI for use in experiments and to study the effect of adding increasing amounts of virus. High efficiencies of gene transfer and expression (Ͼ95% IGROV-1 tumour cells positive) could be obtained using an MOI of 30 p.f.u. per cell. Although an MOI of 30 p.f.u. per cell resulted in a maximal number of cells positive the amount of protein expressed at the cell surface could be increased by increasing the MOI. When a number of ovarian and cervical cell lines were infected at an MOI of 30 most showed efficient gene delivery (27-96% cells positive). As well as efficiently infecting cell lines this vector was also able to transduce primary cultures of ovarian tumour cells with similar high efficiency in six out of seven cases.
An approach that did not rely upon culture of tumour cells would be the most convenient method for delivering therapeutic genes. We have found that suspensions of ovarian tumour cells within 24 h of separation from ascitic fluid or immediately following removal from liquid nitrogen could also be infected with RAd-B7-1. These tumour cells are present as clumps of cells and therefore an accurate MOI is difficult to achieve and cells cannot be FACS analysed, but immunofluorescence staining has shown gene transfer and expression (data not shown). These results are similar to those reported by Dessureault et al 30 who showed efficient B7-1 gene transfer to a number of cell lines and dissociated primary tumours using a recombinant adenovirus. This study did not include ovarian tumour cells and the immunogenicity of modified cells was not reported. The mechanism underlying the resistance of some tumour cells (particularly ovarian cell line A2780) to infection with adenovirus is under investigation. A2780 cells express high levels of MHC class I and the integrin vitronectin molecules (data not shown) important for virus attachment and internalisation, suggesting that the mechanism underlying resistance lies elsewhere.
The capacity of tumour cells expressing B7-1 to stimulate allogeneic PBLs was determined by a mixed lymphocyte tumour cell assay. Tumour cells expressing B7-1 induced significantly higher levels of proliferation than control cells and this was found to be directly attributable to B7-1 as antibodies against this molecule were found to block the response. Similar levels of proliferation (twoto six-fold compared with control cultures) to those reported here for the cervical tumour cell line HeLa have been reported by Kaufmann et al 31 the suppressive effects only become apparent in the MLTC when sufficient tumour cells are present. To determine if an increased proliferative response was seen using freshly isolated tumour cells rather than established cell lines, ascitic ovarian tumour cells and early passage cultures from a solid ovarian tumour were modified to express B7-1 then used as stimulators in mixed lymphocyte tumour cell cultures. Primary cells gave a pattern of response similar to that seen using established cell lines. In addition to the proliferation data shown in this report, a number of the other cervical and ovarian cell lines, as well as primary ovarian tumour cells have been used in the MLTC assay and increased proliferation to B7-1 expressing cells has always been detected (data not shown). Although this assay confirms that the B7-1 molecule is biologically active and that ovarian and cervical tumour cells are immunogenic the issue of antigenicity is not addressed. This would need to be studied in an autologous setting through generation of a specific CD4 + and/or CD8 + T cell response. It is already well recorded that a variety of tumour cells express specific antigens including melanoma, [33] [34] [35] ovary, 20-22 breast, 22, 36 and cervical carcinoma. 37 It therefore appears possible that B7-1 transfer into tumour cells could be used as a means to generate a cellular vaccine which could then be used to elicit tumour-specific CTL response. When considering the extension of the present investigation to its clinical application, the possible combined use of cytokine genes, in particular IL-2 will need to be explored. This is in the light of a number of animal studies which have reported more effficient tumour regression and systemic immunity using both B7-1 and IL-2 in combination rather than either gene on its own. 38, 39 In conclusion, the results reported here demonstrate that the adenoviral vector is a rapid and efficient means of gene delivery to ovarian and cervical tumour cells. The results demonstrate that B7-1 expression in human ovarian and cervical tumour cells increases their immunogenicity, as evaluated using proliferation of allogeneic PBL. These data support the rationale for potential use of adenovirally delivered B7-1 for genetic immunotherapy of ovarian and cervical cancer.
Materials and methods
Preparation of primary ovarian tumour cells Malignant ascites were obtained from patients with epithelial adenocarcinoma of the ovary. Heparinised ascitic fluid was centrifuged at 800 g for 15 min and the cell pellet resuspended in serum-free RPMI 1640 culture medium. Live cells were separated from red blood cells and dead cells by centrifugation through Ficoll-Hypaque (Lymphoprep; Nycomed Pharma, Oslo, Norway). Tumour cells were then separated from mononuclear cells by centrifugation on 75/100% discontinuous FicollHypaque gradients. 20 Ovarian tumour cells were maintained in culture in DME medium supplemented with 10% foetal bovine serum (FBS), 1% glutamine, 1% penicillin and streptomycin, 1% nonessential amino acids (Life Technologies, Paisley, UK)) and 10 g/ml insulin (Sigma, Poole, UK).
Ovarian cell line OvCaMG75 was generated from an epithelial ovarian tumour by collagenase digestion. In 972 brief, the tumour was minced manually into small fragments then enzymatically dispersed to yield a single cell suspension by digestion for 4 h in 3% collagenase type I (Sigma), 0.02% DNase (Sigma) in serum-free DME plus 20 mm hepes and 1% penicillin and streptomycin. Tumour cells were cultured in 6-cm Petri dishes preseeded with a confluent monolayer of irradiated NIH3T3 cells (60 Gy, cobalt 60) to prevent the outgrowth of fibroblasts. OvCaMG75 cells were grown in RPMI 1640 supplemented with 1% glutamine, 1% penicillin and streptomycin, and 10% FBS.
Tumour cell lines
Human cervical tumour cell lines SiHa, MS751, ME-180, HT-3, C-33A, C-4I and ovarian tumour cell lines OVCAR3 and Caov3 were obtained from the American Type Culture Collection (Rockville, MD, USA). OAW28, OAW42, 59M and 41M ovarian tumour cell lines were provided by Dr G Ganeshan, John Radcliffe Hospital, Oxford, UK. IGROV-1 cells were kindly provided by Dr Martin Ford, Glaxo Wellcome Research Laboratories, Stevenage, UK. The ovarian cell line A2780 was provided by Dr J Plumb, Glasgow University, Glasgow, UK. The above cervical cell lines were grown in RPMI 1640 supplemented with 1% glutamine and 10% FBS. Cervical tumour cells CaSki and HeLa were cultured in DME supplemented with 1% glutamine and 10% FBS. Apart from IGROV-1 and A2780 cells which were grown in RPMI-1640, the ovarian cell lines were grown in DME supplemented as above. Cell lines 59M and 41M required in addition supplements of 10 g/ml insulin and 1 mm sodium pyruvate (Life Technologies). Cell line OVCAR3 required the addition of 1% nonessential amino acids and 10 g/ml insulin. All cell lines were subcultured weekly and routinely checked for mycoplasma contamination.
Construction of recombinant Ad-CMV-B7-1 virus (RAd-B7-1) Human B7-1 cDNA was generously provided by Dr M Jenkins (Minnesota, MN, USA) in the expression vector pcEXV-hB7. 11 This was cut with EcoRI and the B7 fragment (919 bp) gel-purified and inserted downstream of the CMV immediate-early promoter in the retroviral vector plasmid pLNCX (kindly provided by AD Miller, Fred Hutchinson Cancer Research Center, Seattle, WA, USA) to yield plasmid pxLNC-hB7. Plasmid pPS971C5 contains the first part of the adenovirus sequence up to the XbaI site at 10 589 base pairs, but has been deleted for the whole of the E1a and the majority of the EIb region of Ad5. The deleted region is replaced by a unique BamHI cloning site, and by splice and poly A/termination signals from the human beta globin gene and the human complement C2 genes, respectively. The human B7-1 was subcloned together with the CMV immediate-early promoter into the BamHI site to give pPS976F11. Plasmid pPS972C10 encompasses the rest of the adenoviral genome from bp 10 589, to the right end, except for a 1878 bp deletion between two XbaI sites in the E3 region (28592 to 30470), which now contains a short polylinker with unique BstBI and PacI sites. Plasmids pPS976F11 and pPS972C10 were linearised with XbaI, ligated together and then partially digested with EcoRI to break up large concatamers, before being transfected by calcium phosphate precipitation into 293 cells. 40 Recombinant virus was rescued, plaque purified (Figure 1 ), grown and titrated as described 41 to give virus stocks for experiments. Recombinant adenovirus RAd35 (an E1/E3 deleted adenovirus carrying the E. coli LacZ gene, 42 kind gift of Dr Gavin Wilkinson, Cardiff University, UK) was used as a control vector.
Infection of tumour cells
RAd-B7-1 was used to infect ovarian and cervical cell lines, and primary cultures of ovarian tumour cells derived from ascites and solid tumour. Tumour cells were cultured to between 50-70% confluence in 6-cm plates; then infection with the recombinant adenovirus was performed in 0.5 ml medium plus 10% FBS at a MOI of between 3 and 1000 p.f.u. per cell for 2 h with occasional agitation. The virus containing medium was removed, replaced by growth medium and cells were harvested by trypsinisation at intervals to study B7-1 expression.
Cell staining and flow cytometry For visualisation of B7-1 expression, trypsinised cells were washed in PBS Dulbecco's A, air-dried for 2 h on to microspot slides then fixed in a 1:1 mix of acetone:methanol for 10 min. Following rehydration in DPBS, cells were stained for 60 min at room temperature with primary antibody BB-1, a murine antibody recognising human B7-1 (Becton Dickinson, Oxford, UK) at a concentration of 10 g/ml. Cells were counterstained with FITC-conjugated goat antimouse antibody (Sigma) for 30 min at room temperature, mounted in DABCO then viewed using a Nikon UV-fluorescense microscope (Nikon, Tokyo, Japan). For flow cytometry cells were harvested by trypsinisation then stained for 60 min at 4°C with primary antibody BB-1, 10 g/ml. Cells were counterstained with FITC conjugated goat antimouse antibody for 30 min at 4°C. Background fluorescence for control staining in FACS assays was set by staining uninfected cells with BB-1 antibody and typically yielded 2% cells positive. No significant differences in control values were detected when cells were stained with an isotype matched irrelevant antibody or when cells were infected with control RAd35 vector before staining (data not shown). Following fixation in 1% paraformaldehyde, cells were analysed on a Coulter XL flow cytometer (Coulter, FL, USA) with standard filter configuration.
Mixed lymphocyte tumour cell cultures (MLTC)
Tumour cells to be used as stimulators were infected with RAd35 or RAd-B7-1 then incubated with 150 U/ml interferon gamma (IFN␥; R&D Systems, Oxford, UK), for 48 h. Following IFN␥ treatment cells expressed high levels of HLA class I and class II as determined by immunocytochemistry and flow cytometry (data not shown). Stimulator cells were harvested by trypsinisation then irradiated at 6000 rad (cobalt 60). Peripheral blood lymphocytes (PBLs) were obtained from normal laboratory donors by separation down Ficoll-Hypaque. 10 5 PBLs were cultured in 96 well round bottomed plates for 6 days with between 2 × 10 2 to 2 × 10 4 irradiated tumour cells. Assays were set up using RPMI 1640 medium supplemented with 1% glutamine and 10% human serum (AB serum; Sigma) in the absence of IL-2. Proliferation was determined by adding 0.5 Ci 3 H-thymidine (Amersham International, Buckinghamshire, UK) to each well for the last 18 h of culture. Cells were harvested on a Skatron plate harvester and 3 H-thymidine uptake measured by liquid scintillation counting. The mean of six wells was determined for each stimulation, and for control PBLs alone. Inhibition of signalling through B7-1 was performed by addition of 2.5 g/ml of antibody to B7 (BB-1) or an isotype control at the initiation of co-culture. The optimum amount of antibody was determined by titration experiments (data not shown).
